The CD166-targeted T lymphocyte treatment discussed above represents a clinically appealing strategy for osteosarcoma patients with positive CD166 expression, offering a starting point for additional investigations of clinical osteosarcoma immunotherapy. This evidence concerns the gene ALCAM and osteosarcoma.